WO2002040044A3 - Chemoattractant recruitment of dendritic cells for enhancement of immunization - Google Patents

Chemoattractant recruitment of dendritic cells for enhancement of immunization Download PDF

Info

Publication number
WO2002040044A3
WO2002040044A3 PCT/US2001/046598 US0146598W WO0240044A3 WO 2002040044 A3 WO2002040044 A3 WO 2002040044A3 US 0146598 W US0146598 W US 0146598W WO 0240044 A3 WO0240044 A3 WO 0240044A3
Authority
WO
WIPO (PCT)
Prior art keywords
dendritic cells
site
antigen
chemoattractant
recruitment
Prior art date
Application number
PCT/US2001/046598
Other languages
French (fr)
Other versions
WO2002040044A2 (en
Inventor
Charles R Maliszewski
Eric A Butz
Laurent J Galibert
Luis G Borges
Original Assignee
Immunex Corp
Charles R Maliszewski
Eric A Butz
Laurent J Galibert
Luis G Borges
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp, Charles R Maliszewski, Eric A Butz, Laurent J Galibert, Luis G Borges filed Critical Immunex Corp
Priority to US10/416,937 priority Critical patent/US20040071657A1/en
Priority to AU2002225927A priority patent/AU2002225927A1/en
Publication of WO2002040044A2 publication Critical patent/WO2002040044A2/en
Publication of WO2002040044A3 publication Critical patent/WO2002040044A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The immune response to an antigen is enhanced through increasing the concentration of dendritic cells at a targeted site, which site may be the site of antigen contact, or may be the site of antigen presentation to T cells. Dendritic cells are attracted to the targeted site by a localization factor, which factor may be chemokine, cytokine, somatostatin receptor agonists, and the like. The methods may further be practised in conjunction with the expansion of functional dendritic cells in vivo, for example through administration of Flt3-L, GM-CSF, and the like. Also included is the use of maturation factors following antigen acquisition by the dendritic cells.
PCT/US2001/046598 2000-11-17 2001-11-14 Chemoattractant recruitment of dendritic cells for enhancement of immunization WO2002040044A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/416,937 US20040071657A1 (en) 2001-11-14 2001-11-14 Chemoattractant recruitment of dendritic cells for enhancement of immunization
AU2002225927A AU2002225927A1 (en) 2000-11-17 2001-11-14 Chemoattractant recruitment of dendritic cells for enhancement of immunization

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24952400P 2000-11-17 2000-11-17
US60/249,524 2000-11-17

Publications (2)

Publication Number Publication Date
WO2002040044A2 WO2002040044A2 (en) 2002-05-23
WO2002040044A3 true WO2002040044A3 (en) 2002-08-22

Family

ID=22943841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/046598 WO2002040044A2 (en) 2000-11-17 2001-11-14 Chemoattractant recruitment of dendritic cells for enhancement of immunization

Country Status (2)

Country Link
AU (1) AU2002225927A1 (en)
WO (1) WO2002040044A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035106A1 (en) * 2001-10-24 2003-05-01 Chemocentryx Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
WO2009043523A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Cortistatin 17 and neuropeptide 1 for use as therapeutic agent

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012633A1 (en) * 1995-10-04 1997-04-10 Immunex Corporation Dendritic cell stimulatory factor
WO1998013382A1 (en) * 1996-09-27 1998-04-02 Amrad Operations Pty. Ltd. A process for culturing cells
CA2256250A1 (en) * 1997-12-17 1999-06-17 James Lillard Method for enhancing an immune response using mitogenic and chemokinetic factors
WO2000022124A2 (en) * 1998-10-15 2000-04-20 Canji, Inc. Methods and compositions to induce antitumor response
WO2000073432A2 (en) * 1999-06-01 2000-12-07 Cornell Research Foundation, Inc. Activation of dendritic cells to enhance immunity
WO2001062275A1 (en) * 2000-02-24 2001-08-30 The Board Of Trustees Of The Leland Stanford Junior University Adjuvant treatment by in vivo activation of dendritic cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012633A1 (en) * 1995-10-04 1997-04-10 Immunex Corporation Dendritic cell stimulatory factor
WO1998013382A1 (en) * 1996-09-27 1998-04-02 Amrad Operations Pty. Ltd. A process for culturing cells
CA2256250A1 (en) * 1997-12-17 1999-06-17 James Lillard Method for enhancing an immune response using mitogenic and chemokinetic factors
WO2000022124A2 (en) * 1998-10-15 2000-04-20 Canji, Inc. Methods and compositions to induce antitumor response
WO2000073432A2 (en) * 1999-06-01 2000-12-07 Cornell Research Foundation, Inc. Activation of dendritic cells to enhance immunity
WO2001062275A1 (en) * 2000-02-24 2001-08-30 The Board Of Trustees Of The Leland Stanford Junior University Adjuvant treatment by in vivo activation of dendritic cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GODISKA R ET AL: "HUMAN MACROPHAGE-DERIVED CHEMOKINE (MDC) A NOVEL CHEMOATTRACTANT FOR MONOCYTES MONOCYTE-DERIVED DENDRITIC CELLS AND NATURAL KILLER CELLS", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 185, no. 9, 5 May 1997 (1997-05-05), pages 1595 - 1604, XP002062732, ISSN: 0022-1007 *
VICARI A P ET AL: "TECK: A NOVEL CC CHEMOKINE SPECIFICALLY EXPRESSED BY THYMIC DENDRITIC CELLS AND POTENTIALLY INVOLVED IN T CELL DEVELOPMENT", IMMUNITY, CELL PRESS, US, vol. 7, no. 2, 1 August 1997 (1997-08-01), pages 291 - 301, XP002048197, ISSN: 1074-7613 *

Also Published As

Publication number Publication date
WO2002040044A2 (en) 2002-05-23
AU2002225927A1 (en) 2002-05-27

Similar Documents

Publication Publication Date Title
Okamoto et al. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation
NZ333607A (en) Method of stimulating the immune system by transfecting dendritic cells
EP2468299A3 (en) Compositions for inducing immune responses
EP2246067A3 (en) Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
AU3607301A (en) Gene recombinant antibody and its fragment
GB9818627D0 (en) Improvements in dva vaccination
EE05633B1 (en) Modified Vaccine Virus Ankara (MVA), an Inhibited Host Cell and a Pharmaceutical Composition Containing It, Preparation and Therapeutic Use of MVA
AU2008265911B2 (en) Use of TLR agonists and/or type 1 interferons to alleviate toxicity of TNF-R agonist therapeutic regimens
WO2004001007A3 (en) Buffered formulations for concentrating antibodies and methods of use thereof
EP2377548A3 (en) Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
HUP9904601A2 (en) Device for local administration of solid and semisolid formulations, sustained-release formulations for parenteral administration and method of preparation
WO2004053072A3 (en) Administration of dendritic cells partially matured in vitro for the treatment of tumors
WO2006057003A3 (en) Induction of neurogenesis and stem cell therapy in combination with copolymer 1
Lynch et al. In vivo evaluation of the effects of interleukins 2, 4 and 7 on enhancing the immunotherapeutic efficacy of anti‐tumor cytotoxic T lymphocytes
WO2002007748A3 (en) Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor
WO2003028757A1 (en) Novel method of inducing antigen-specific t cells
WO2002036141A3 (en) Method of enhancing lymphocyte-mediated immune responses
Lysle et al. Endogenous opioids regulate the expression of inducible nitric oxide synthase by splenocytes
EP1932915A3 (en) Materials and methods relating to improved vaccination strategies
CA2337754A1 (en) Recombinant multivalent malarial vaccine against plasmodium falciparum
WO2004053095A3 (en) In situ maturation of dendritic cells
WO2002040044A3 (en) Chemoattractant recruitment of dendritic cells for enhancement of immunization
IL139601A0 (en) Compositions and methods of modulating an immune response to an antigen
ATE319833T1 (en) VACCINES TO INCREASE IMMUNE RESPONSES AGAINST HERPES SIMPLEX VIRUS
WO2002053176A3 (en) An autologous anti-cancer vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10416937

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP